Agenus (NASDAQ:AGEN) Receives Buy Rating from HC Wainwright

Agenus (NASDAQ:AGEN)‘s stock had its “buy” rating reissued by analysts at HC Wainwright in a report issued on Tuesday, Benzinga reports. They presently have a $40.00 target price on the biotechnology company’s stock. HC Wainwright’s price objective points to a potential upside of 248.74% from the company’s previous close.

AGEN has been the subject of several other reports. B. Riley dropped their target price on shares of Agenus from $120.00 to $100.00 and set a “buy” rating for the company in a research report on Monday, March 18th. StockNews.com initiated coverage on Agenus in a research note on Wednesday, April 17th. They set a “hold” rating for the company.

Agenus Price Performance

Agenus stock opened at $11.47 on Tuesday. The firm has a market cap of $232.67 million, a PE ratio of -0.81 and a beta of 1.25. The stock’s fifty day moving average price is $10.71 and its two-hundred day moving average price is $13.23. Agenus has a one year low of $4.78 and a one year high of $42.60.

Agenus (NASDAQ:AGEN) last released its earnings results on Thursday, March 14th. The biotechnology company reported ($2.60) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.40) by ($2.20). The firm had revenue of $83.80 million during the quarter, compared to the consensus estimate of $54.21 million. Sell-side analysts expect that Agenus will post -8.21 earnings per share for the current fiscal year.

Insider Activity

In related news, insider Garo H. Armen acquired 25,000 shares of the company’s stock in a transaction that occurred on Thursday, February 15th. The stock was acquired at an average price of $13.00 per share, with a total value of $325,000.00. Following the purchase, the insider now directly owns 31,298 shares in the company, valued at $406,874. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 4.80% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Agenus

Institutional investors and hedge funds have recently bought and sold shares of the company. SG Americas Securities LLC bought a new stake in shares of Agenus during the third quarter worth about $36,000. PCG Wealth Advisors LLC increased its position in Agenus by 65.7% in the 4th quarter. PCG Wealth Advisors LLC now owns 47,550 shares of the biotechnology company’s stock valued at $39,000 after acquiring an additional 18,850 shares during the period. RPO LLC acquired a new position in Agenus in the 4th quarter valued at approximately $43,000. Lindbrook Capital LLC raised its stake in shares of Agenus by 38.8% during the third quarter. Lindbrook Capital LLC now owns 52,535 shares of the biotechnology company’s stock valued at $59,000 after acquiring an additional 14,674 shares during the last quarter. Finally, Ables Iannone Moore & Associates Inc. acquired a new position in shares of Agenus during the fourth quarter worth $65,000. Institutional investors and hedge funds own 61.46% of the company’s stock.

About Agenus

Agenus Inc, a clinical-stage biotechnology company, discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies.